Investigational Janus kinase inhibitors in development for myelofibrosis.

Abstract:

INTRODUCTION:Since the discovery of the activating V617F mutation in Janus kinase 2 (JAK2), a number of pharmacologic inhibitors of JAK2 have entered clinical trials for patients with myelofibrosis. However, ruxolitinib, approved in 2011, remains the only one currently available for treatment of myelofibrosis, with many others having been discontinued for toxicity, and considerable uncertainty surrounding the future of those still in development. Areas covered: The available clinical data on pacritinib and momelotinib, the two agents in the most advanced phases of clinical testing in myelofibrosis, are examined in detail. NS-018 and INCB039110, selective inhibitors of JAK2 and JAK1, respectively, are also discussed. Finally, the JAK2 inhibitors no longer in clinical development are summarized in tabular form. Expert opinion: The different agents evaluated clearly differ in their kinomes, toxicity profiles and potential for myelosuppression. If approved, the JAK2-specific non-myelosuppressive inhibitor pacritinib could fulfill a major unmet need, that of patients with significant cytopenias. However, toxicity concerns persist. The data from the pivotal trials of momelotinib do not support its approval, although improvement of anemia is an important benefit. Selective JAK1 inhibition alone is unlikely to succeed in myelofibrosis. In these circumstances, rational ruxolitinib-based combinations may represent the best way forward.

authors

Bose P,Abou Zahr A,Verstovsek S

doi

10.1080/13543784.2017.1323871

subject

Has Abstract

pub_date

2017-06-01 00:00:00

pages

723-734

issue

6

eissn

1354-3784

issn

1744-7658

journal_volume

26

pub_type

杂志文章,评审
  • Immunotherapy in atopic dermatitis.

    abstract::Atopic dermatitis (AD) is a common inflammatory disease involving the skin and often other organs and systems, mainly respiratory. A definitive general consensus on the AD pathogenesis has not yet been established, however several lines of evidence suggest that T-cells play a crucial role in priming AD early-stage les...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.1.49

    authors: Mastrandrea F

    更新日期:2001-01-01 00:00:00

  • Emerging therapeutic interventions against noise-induced hearing loss.

    abstract:INTRODUCTION:Noise-induced hearing loss (NIHL) due to industrial, military, and recreational noise exposure is a major, but also potentially preventable cause of acquired hearing loss. For the United States it is estimated that 26 million people (15% of the population) between the ages of 20 and 69 have a high-frequenc...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1269171

    authors: Sha SH,Schacht J

    更新日期:2017-01-01 00:00:00

  • Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004.

    abstract::Recent advances in the treatment and management of haematological malignancies are due in large part to an improved understanding of the basic biology that drives tumour cell growth and survival. This improved understanding has led to the clinical study and approval of a number of different targeted agents across a nu...

    journal_title:Expert opinion on investigational drugs

    pub_type:

    doi:10.1517/13543784.14.9.1161

    authors: Haas M,Lonial S

    更新日期:2005-09-01 00:00:00

  • Insulin aspart: a novel rapid-acting human insulin analogue.

    abstract::In order to improve therapy and increase the quality of life for diabetic patients, it has been of significant interest to develop rapid-acting insulin preparations that mimic the physiological meal-time profile of insulin more closely than soluble human insulin. Insulin aspart (B28Asp human insulin) is a novel rapid-...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.8.9.1431

    authors: Gammeltoft S,Hansen BF,Dideriksen L,Lindholm A,Schäffer L,Trüb T,Dayan A,Kurtzhals P

    更新日期:1999-09-01 00:00:00

  • Histopathological prognostic factors in early breast carcinoma: an evaluation of cell proliferation in carcinoma cells.

    abstract::Early breast carcinoma is defined as pathological stage 1 (pT1N0M0) tumour and its incidence has recently increased possibly due to the advent of mammography based mass screening. Overall survival of these patients is in general excellent, but more than 20% of them will eventually develop distant metastasis and die. T...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543781003718833

    authors: Sasano H

    更新日期:2010-04-01 00:00:00

  • Novel GLP-1 receptor agonists for diabetes.

    abstract:INTRODUCTION:GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, exenatide, was approved in the mid-2000s, other agents with longer durations of action (that do not require twice-daily dosing) are now being developed. In...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.638282

    authors: Garber AJ

    更新日期:2012-01-01 00:00:00

  • Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.

    abstract::Major depressive disorder (MDD) affects

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903286396

    authors: Khan A

    更新日期:2009-11-01 00:00:00

  • CDK inhibitors in clinical development for the treatment of cancer.

    abstract::Cyclin-dependent protein kinases (CDKs) are key regulators of the cell division cycle, whose various checkpoints proliferating cells must traverse. Since CDK deregulation, either through direct or indirect means, is found in most cancer cells, pharmacological CDK inhibition has become an attractive strategy towards me...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.6.955

    authors: Fischer PM,Gianella-Borradori A

    更新日期:2003-06-01 00:00:00

  • Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.

    abstract:INTRODUCTION:Fibroblast growth factor receptors (FGFR 1-4) are a highly conserved family of receptor tyrosine kinases, involved in several physiological processes. Genetic aberrations of FGFRs and their ligands, fibroblast growth factors (FGFs) are involved in several pathological processes including cancer. The FGF-FG...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1838484

    authors: Chandana SR,Babiker HM,Mahadevan D

    更新日期:2020-12-01 00:00:00

  • Microbial pathogens and apoptotic anticancer therapy.

    abstract::In spite of tremendous efforts to control cancer, the mortality associated with this disease has been increasing in developed countries in the recent decades. Inadequate efficiency of existing therapeutic regimens and the rise of multi-drug resistant cancer cells are the main factors which require a broadening of inve...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.6.1243

    authors: Pasechnik V

    更新日期:2000-06-01 00:00:00

  • Does the small tyrosine kinase inhibitor Imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?

    abstract:INTRODUCTION:The small tyrosine kinase inhibitor Imatinib Mesylate (Gleevec) protects against diabetes, but it is not known how. AREAS COVERED:It has been suggested that islet amyloid and fibrotic deposits promote beta-cell failure and death, leading to Type-2 diabetes. As Imatinib is known to possess anti-fibrotic/am...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.724398

    authors: Welsh N

    更新日期:2012-11-01 00:00:00

  • Alpha-lipoic acid, an anti-obesity agent?

    abstract::Obesity shortens life expectancy and is a risk factor for hypertension and Type 2 diabetes. When added to the standard chow of Sprague-Dawley or Otsuka Long-Evans Tokushima Fatty rats, alpha-lipoic acid (0.5% weight/weight) reduced body weight and food intake. Alpha-lipoic acid also increased whole-body energy expendi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.12.1641

    authors: Doggrell SA

    更新日期:2004-12-01 00:00:00

  • Akt inhibitors in clinical development for the treatment of cancer.

    abstract:IMPORTANCE OF THE FIELD:The evolution of targeted therapies is dependent upon identification of cellular moieties that can be pharmacologically modulated. As one such example, the serine-threonine kinase Akt was identified nearly two decades ago. Since then, its role in mediating multiple signaling cascades (ultimately...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.520701

    authors: Pal SK,Reckamp K,Yu H,Figlin RA

    更新日期:2010-11-01 00:00:00

  • Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.

    abstract:INTRODUCTION:Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. AREAS COVERED:We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgk...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2018.1416091

    authors: Chang A,Schlafer D,Flowers CR,Allen PB

    更新日期:2018-01-01 00:00:00

  • Na+ H+ exchanger-1: a link with atherogenesis?

    abstract:IMPORTANCE OF THE FIELD:The sodium/hydrogen exchanger-1 (NHE-1/SLC9A1) is a ubiquitous plasma membrane protein whose main role is maintenance of intracellular pH and volume. NHE-1 plays a role in atherogenesis; however, its clinical relevance has not yet been established. AREAS COVERED IN THIS REVIEW:We herein review ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.532123

    authors: Sarigianni M,Tsapas A,Mikhailidis DP,Kaloyianni M,Koliakos G,Fliegel L,Paletas K

    更新日期:2010-12-01 00:00:00

  • Treatment of neurodegenerative diseases with neural cell transplantation.

    abstract::Neural cell transplantation is an emerging therapy that may provide an effective treatment for neurodegenerative disorders. The most extensive work with neural transplants has been carried out for Parkinson's and Huntington's diseases. However, intensive efforts are also being made for the treatment of other neurologi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.4.527

    authors: Dinsmore JH

    更新日期:1998-04-01 00:00:00

  • Recent and ongoing clinical trials for treating colorectal cancer.

    abstract::Colorectal cancer is one of the most common cancers worldwide. Through well-designed clinical trials, advances have been made in the treatment of localised and advanced colorectal cancer. It has been established that 6 months of 5-fluorouracil-based chemotherapy will improve overall survival in patients with stage III...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.6.871

    authors: Mulcahy MF,Benson AB 3rd

    更新日期:2002-06-01 00:00:00

  • Pioglitazone for the treatment of Alzheimer's disease.

    abstract:INTRODUCTION:Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Pharmacological treatment of AD includes Anticholinesterase Inhibitors (AChEIs) for mild-moderate AD, and memantine for severe AD. These drugs provide mainly symptomatic short-term benefits without clearly influencing the progres...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1265504

    authors: Galimberti D,Scarpini E

    更新日期:2017-01-01 00:00:00

  • Therapeutic developments in multiple sclerosis.

    abstract::Recently there have been considerable advances made in the treatment of multiple sclerosis. For the first time since its initial clinical description in the 1800s, there are now available several medications which unequivocally exert favourable clinical effects through the lowering of the biological activity of the hu...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.4.655

    authors: Goodin DS

    更新日期:2000-04-01 00:00:00

  • How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.

    abstract:INTRODUCTION:Relapsed/refractory multiple myeloma (rrMM) remains a difficult condition to treat despite the availability of new drugs. This review aims to provide evidence to guide physicians in the choice of salvage therapy in certain subgroups of patients. AREAS COVERED:The review attempts to present evidence-based ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2011.575060

    authors: Offidani M,Corvatta L,Morabito F,Gentile M,Musto P,Leoni P,Palumbo A

    更新日期:2011-06-01 00:00:00

  • Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.

    abstract:BACKGROUND:Histone deacetylases (HDACs), which target histones as well as non-histone proteins as substrates, have the potential to regulate aberrant gene expression and restore normal growth control in malignancies. OBJECTIVE:This review provides an updated summary of preclinical and clinical experience with the oral...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.8.1247

    authors: Le Tourneau C,Siu LL

    更新日期:2008-08-01 00:00:00

  • The therapeutic potential of monoclonal antibodies against respiratory syncytial virus.

    abstract::Attempts to develop a vaccine against respiratory syncytial virus (RSV), the major cause of lower respiratory tract disease in infants and young children, have been unsuccessful. Passive immunisation with antibody to RSV has been found to be an effective alternative method for prophylaxis. The product currently in use...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.8.1271

    authors: Weltzin R

    更新日期:1998-08-01 00:00:00

  • Anti-adhesive strategies in the prevention of infectious disease at mucosal surfaces.

    abstract::Binding of microbial cell surface adhesins to host receptor molecules is a critical early step in microbial infection and pathogenesis. Anti-adhesive strategies aimed at blocking this interaction offer an attractive means of preventing infection at an early stage. The strategy should reduce the likelihood of resistant...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.8.1711

    authors: Kelly CG,Younson JS

    更新日期:2000-08-01 00:00:00

  • Therapeutic use of the high-density lipoprotein protein and peptides.

    abstract::High-density lipoprotein (HDL) therapy is a novel and emerging area of therapeutic development in the cardiovascular field. It attempts to supplement and improve the vascular benefit exerted by other agents that are active on lipid metabolism, for example, hypolipidaemic drugs. Furthermore, it takes advantage of the n...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.3.227

    authors: Marchesi M,Sirtori CR

    更新日期:2006-03-01 00:00:00

  • Angiotensin II type 2 receptor agonists--where should they be applied?

    abstract::It is now widely accepted that the renin-angiotensin system (RAS) not only contributes to pathological mechanisms involved, e.g. in hypertension or hypertensive and diabetic end-organ damage, but also harbors a "protective arm" represented mainly by two receptors, the AT2 (angiotensin type 2) receptor and the Mas rece...

    journal_title:Expert opinion on investigational drugs

    pub_type: 评论,杂志文章

    doi:10.1517/13543784.2012.681046

    authors: Steckelings UM,Unger T

    更新日期:2012-06-01 00:00:00

  • Aromatase inhibitors for the treatment of infertility.

    abstract::Ovarian stimulation during infertility treatment is used either alone or in conjunction with intrauterine insemination and assisted reproductive technologies. At the present time, the two main medications used for ovarian stimulation include an oral antioestrogen, clomiphene citrate and injectable gonadotrophins. In s...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.3.353

    authors: Mitwally MF,Casper RF

    更新日期:2003-03-01 00:00:00

  • Developments with experimental and investigational drugs for axial spondyloarthritis.

    abstract:INTRODUCTION:Axial spondyloarthritis (AxS pA) is a chronic inflammatory disease for which, until recently, there were no valid therapeutic alternatives to TNF-α blocking agents. This unmet clinical need led to explore several therapeutic targets, from proinflammatory cytokines to intracellular signaling systems. The re...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1337744

    authors: Clavel G,Boissier MC,Sigaux J,Semerano L

    更新日期:2017-07-01 00:00:00

  • Proteasome inhibitors: possible novel therapeutic strategy for ischemia-reperfusion injury?

    abstract:INTRODUCTION:The ubiquitin-proteasome system (UPS) is responsible for the degradation of misfolded or damaged proteins, regulating inflammatory processes and cell cycle progression. The aim of this article is to summarize the currently available data regarding the possible utility of proteasome inhibitors (PIs) in the ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2013.840287

    authors: Kandilis AN,Karidis NP,Kouraklis G,Patsouris E,Vasileiou I,Theocharis S

    更新日期:2014-01-01 00:00:00

  • Glucokinase activators in diabetes management.

    abstract::Type 2 diabetes is a chronic metabolic disease that adversely affects both the quality and longevity of life. The disease is characterised by elevated blood glucose (hyperglycaemia) that is associated with microvascular complications and increased macrovascular risk. Existing oral agents, either alone or in combinatio...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.2.145

    authors: Coghlan M,Leighton B

    更新日期:2008-02-01 00:00:00

  • Perspectives in therapy for hepatitis C.

    abstract:BACKGROUND:Chronic hepatitis C virus (HCV) infection is a worldwide health problem. Response rates to current standard of treatment (pegylated IFNs and ribavirin) are low in patients with the prevailing genotype 1. OBJECTIVE:To review papers published or presented at recent international meetings showing the results o...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.11.1635

    authors: Vento S,Cainelli F,Temesgen Z

    更新日期:2008-11-01 00:00:00